Gain Therapeutics, Inc. (GANX)
GANX Stock Price Chart
Explore Gain Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GANX price movements and trends.
GANX Company Profile
Discover essential business fundamentals and corporate details for Gain Therapeutics, Inc. (GANX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Mar 2021
Employees
23.00
Website
https://www.gaintherapeutics.comCEO
Gene Mack
Description
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
GANX Financial Timeline
Browse a chronological timeline of Gain Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.14, while revenue estimate is $33.33k.
Earnings released on 11 May 2026
EPS came in at -$0.13 matching the estimated -$0.13.
Earnings released on 26 Mar 2026
EPS came in at -$0.11 surpassing the estimated -$0.14 by +21.43%.
Earnings released on 12 Nov 2025
EPS came in at -$0.15 matching the estimated -$0.15.
Earnings released on 12 Aug 2025
EPS came in at -$0.19 falling short of the estimated -$0.17 by -11.76%.
Earnings released on 14 May 2025
EPS came in at -$0.16 matching the estimated -$0.16.
Earnings released on 27 Mar 2025
EPS came in at -$0.11 surpassing the estimated -$0.18 by +38.89%.
Earnings released on 14 Nov 2024
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%.
Earnings released on 8 Aug 2024
EPS came in at -$0.42 falling short of the estimated -$0.31 by -35.48%.
Earnings released on 14 May 2024
EPS came in at -$0.22 surpassing the estimated -$0.30 by +26.67%.
Earnings released on 26 Mar 2024
EPS came in at -$0.29 surpassing the estimated -$0.32 by +9.38%, while revenue for the quarter reached $64.80k , missing expectations by -79.75%.
Earnings released on 14 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.47 by +21.28%.
Earnings released on 10 Aug 2023
EPS came in at -$0.62 falling short of the estimated -$0.33 by -87.88%.
Earnings released on 12 May 2023
EPS came in at -$0.43 falling short of the estimated -$0.40 by -7.50%, while revenue for the quarter reached $55.18k , beating expectations by +451.80%.
Earnings released on 23 Mar 2023
EPS came in at -$0.39 falling short of the estimated -$0.37 by -5.41%, while revenue for the quarter reached $140.11k , beating expectations by +1.30k%.
Earnings released on 10 Nov 2022
EPS came in at -$0.38 surpassing the estimated -$0.46 by +17.39%.
Earnings released on 8 Aug 2022
EPS came in at -$0.43 falling short of the estimated -$0.35 by -22.86%, while revenue for the quarter reached $95.10k , beating expectations by +200.32%.
Earnings released on 16 May 2022
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $45.01k , beating expectations by +15.40%.
Earnings released on 24 Mar 2022
EPS came in at -$0.25 surpassing the estimated -$0.49 by +48.98%, while revenue for the quarter reached $36.34k , missing expectations by -29.57%.
Earnings released on 12 Nov 2021
EPS came in at -$0.39 falling short of the estimated -$0.34 by -14.71%, while revenue for the quarter reached $27.35k , beating expectations by +100.74%.
Earnings released on 11 Aug 2021
EPS came in at -$0.30 surpassing the estimated -$0.31 by +3.23%, while revenue for the quarter reached $89.17k , beating expectations by +5.84%.
GANX Stock Performance
Access detailed GANX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
